Validation of a standardized method for enumerating circulating endothelial cells and progenitors: Flow cytometry and molecular and ultrastructural analyses

Clinical Cancer Research

Volumn 15, Issue 1, 2009, Pages 267-273

  Mancuso, Patrizia ^a   Antoniotti, Pierluigi ^a   Quarna, Jessica ^a   Calleri, Angelica ^a   Rabascio, Cristina ^a   Tacchetti, Carlo ^b   Braidotti, Paola ^c   Wu, Hua Kang ^d   Zurita, Amado J ^d   Saronni, Luca ^a   Cheng, John B ^e   Shalinsky, David R ^e   Heymach, John V ^d   Bertolini, Francesco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF TEXAS   (United States)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD146 ANTIGEN; CD31 ANTIGEN; CD45 ANTIGEN; DNA; MESSENGER RNA; VASCULAR ENDOTHELIAL CADHERIN;

ADULT; APOPTOSIS; ARTICLE; CANCER PATIENT; CELL DEATH; CELL POPULATION; CELL ULTRASTRUCTURE; CELL VIABILITY; CONTROLLED STUDY; CRYOPRESERVATION; ELECTRON MICROSCOPY; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STANDARDIZATION; STEM CELL; STRUCTURE ANALYSIS; THAWING; THROMBOCYTE; VALIDATION STUDY; WEIBEL PALADE BODY;

CELL COUNT; CELL SURVIVAL; ENDOTHELIAL CELLS; FLOW CYTOMETRY; HUMANS; MICROSCOPY, ELECTRON; NEOPLASMS; REPRODUCIBILITY OF RESULTS; STEM CELLS; WEIBEL-PALADE BODIES;

EID: 58849156504     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0432     Document Type: Article

References (22)

1. Blann AD, Woywodt AD, Bertolini F, et al. Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost 2005;93:228-35.
2. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. Themultifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006;6:835-45.
3. Bertolini F, Mancuso P, Shaked Y, Kerbel RS. Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov Today 2007;12:806-12.
4. Shaked Y, Kerbel RS. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res 2007;67:7055-8.
5. Mancuso P, Colleoni M, Calleri A, et al. Circulating endothelial cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006;108:452-9.
6. Norden-Zfoni A, Desai J, Manola J, et al. Blood- based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007; 13:2643-50.
7. Furstenberger G, von Moos R, Lucas R, et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 2006;94:524-31.
8. Zhang H, Vakil V, Braunstein M, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005;105: 3286-94.
9. Rademaker-Lakhai JM, Beerepot LV, Mehra N, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase Cβ-inhibitor enzas- taurin in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res 2007;13:4474 - 81.
10. Farace F, Massard C, Borghi E, BidartJM, Soria JC. Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells. Ann Oncol 2007;18:1421 -2.
11. Willett CG. Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specif ic antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7.
12. Van Craenenbroeck EM, Conraads VM, Van Bock- staele DR, et al. Quantification of circulating endothelial progenitor cells: a methodological comparison of six flow cytometric approaches. J Immunol Methods Epub 2008.
13. Strijbos MH, Kraan J, den Bakker MA, Lambrecht BN, Sleijfer S, Gratama JW. Cells meeting our immunophenotypic criteria of endothelial cells are large platelets. Cytometry B Clin Cytom 2007;72:86-93.
14. Strijbos MH, Kraan J, Sleijfer S, Gratama J W. Potential biomarkers in metastatic gastrointestinal stromal tumors. Clin Cancer Res 2007;13:6244.
15. van der Pol MA, Broxterman HJ, Westra G, Ossenkoppele GJ, Schuurhuis GJ. Novel multiparameter flow cytometry assay using Syto16 for the simultaneous detection of early apoptosis and apoptosis-corrected P-glycoprotein function in clinical samples. Cytometry B Clin Cytom 2003;55:14-21.
16. Confalonieri S, Salcini AE, Puri C, Tacchetti C, Di Fiore PP. Tyrosine phosphorylation of Eps15 is required for ligand-regulated, but not constitutive, endocytosis. J Cell Biol 2000;150:905-12.
17. Rabascio C, Muratori E, Mancuso P, et al. Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res 2004;64: 4373-7.
18. de Boer F, Drager AM, Pinedo HM, et al. Extensive early apoptosis in frozen-thawed CD34-positive stem cells decreases threshold doses for haematological recovery after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant 2002; 29:249-55.
19. Moldovan Nl. Moldovan L, Simionescu N. Binding of vascular anticoagulant α (Annexin V) to the aortic intima of the hypercholesterolemic rabbit. An autoradiographic study. Blood Coagul Fibrinolysis 1994;5: 921 -8.
20. Rafii S, Lyden D. A few to flip the angiogenic switch. Science 2008;319:163-4.
21. Gratama JW, Kraan J, Keeney M, Sutherland DR, Granger V, Barnett D. Validation of the single- platform ISHAGE method for CD34(+) hematopoietic stem and progenitor cell enumeration in an international multicenter study. Cytotherapy 2003; 5:55-65.
22. Levering WH, van Wieringen WN, Kraan J, et al. Flow cytometric lymphocyte subset enumeration: 10 years of external quality assessment in the Benelux countries. Cytometry B Clin Cytom. Epub 2007 Sep 11.